Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLURP: Fluorescence molecular endoscopy with oral and topical bevacizumab-800CW and cetuximab-800CW in Barrett's esophagus
2023-503801-12-00Phase 2Completed
- Sponsor
- University Medical Center Groningen
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab and cetuximab in Barrett's esophagus, esophageal adenocarcinoma (EAC) and esophageal dysplasia, sponsored by University Medical Center Groningen. Primary endpoints: Feasibility and safety of oral tracer administration and Effect of combined tracer administration on lesion detection. Started May 2023; status: completed.
02
Drugs
bevacizumabcetuximab
03
Conditions
Barrett's esophagusesophageal adenocarcinoma (EAC)esophageal dysplasia
Beyond the preview
Go deeper on 2023-503801-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503801-12-00.